The State of Clinical Trial Access
The State of Clinical Trial Access: Diversity, Enrollment, and What the Data Shows
When we take a look at clinical trial enrollment data, we are reminded of a truth we don't say loud enough, innovation doesn't equal access. We celebrate scientific breakthroughs like they belong to everyone, but in reality, they are far more unevenly distributed. The people who need these breakthroughs the most are usually the ones left out of the trials entirely. Now, with the FDA pushing the industry towards greater accountability, we are being forced to confront a question that has been ignored for too long, who actually gets to participate in the future of medicine?
A Regulatory Turning Point
This moment feels like a turning point. The FDA's new Diversity Action Plan requirements mandate that many late stage trials outline how they will recruit participants who mirror the real-world populations affected by the disease. This regulation acknowledges what researchers, advocates, and patients have been saying for years, which is that clinical trials don't reflect America's diversity. For a long time, diversity in clinical research was considered ideal but never truly materialized. Now, regulatory requirements are changing that. At the same time, the industry is struggling with persistent enrollment failures. Research shows that 70–80% of trials miss recruitment timelines and up to 30% are terminated early because of poor enrollment. These delays slow drug development and shape who ultimately benefits from new treatments. When the people most affected by a disease aren't represented in research, the science is incomplete.
Who Gets Left Out and Why?
The FDA didn't introduce Diversity Action Plans because the inequality was subtle. They did it because the evidence is clear. Racial and ethnic minorities, older adults, rural communities, and people with limited English proficiency remain consistently underrepresented in clinical trials. It is not because they are uninterested and it is because the system was not built with them in mind. Research sites are predominantly located in areas that prioritize institutional access over patient convenience. Transportation, childcare, rigid visit schedules, and inconsistent language access all create barriers. When the structure of clinical research assumes that patients will rearrange their lives to fit a protocol, it should not be surprising that diversity suffers.
The Information Gap
Information barriers make the problem even worse. One of the clearest patterns across the research is that people don't participate in trials because they don't know how to find them. clinicaltrails.gov is broad, but it is not built for patients. The language is dense, filters are confusing, and listings are not always current. Even clinicians struggle to identify relevant trials for their patients, and many assume trials are only available at academic medical centers. Patients who want to explore clinical research are often met with terminology only a medical professional could parse, creating uncertainty before they even begin. This is where clinical trial matching services become essential. Platforms like findmyclinicaltrial.org, translate complex protocols into something understandable and help individuals determine whether they qualify.
Policy Is Just the Start
Policy changes have the potential to reshape access to clinical trials, but only if implementation follows through. The FDA's Diversity Action Plan requirements could push sponsors to rethink how and where they conduct research. However, a plan on paper does not guarantee meaningful change. It starts with placing research sites in the communities where people actually live and partnering with organizations patients already trust. It also means communicating in ways that feel familiar, building in remote or hybrid options when possible, loosening rigid visit schedules, and bringing patient advocates into the conversation before protocols are finalized. These are not optional upgrades. They are what separate a trial that only reaches the most resourced patients from one that actually reflects the people living with the condition. If policy compels sponsors to build these approaches into how trials are designed, we may finally see a real shift in accessibility. If diversity plans become another box to check, the same communities will continue to be left out.
What the Numbers Keep Saying
The data across sources has been consistent. Seventy to eighty percent of trials miss enrollment timelines, up to 30% end early because of poor recruitment, and only a quarter meet their enrollment goals. Minority groups continue to be significantly underrepresented, and most patients never hear about trials from their providers, even when they may be eligible. I have spoken with patients who assumed clinical trials were for "other people" people with better insurance, more severe cases, more time, more connections. I have seen how a simple, clear explanation of eligibility can turn confusion into clarity. This is what happens when a system assumes patients will figure everything out on their own. Research is not built around their day to day reality, so the burden falls on them. The impact is visible everywhere.
Where We Go From Here
The FDA's Diversity Action Plan requirements are pushing the industry to pay closer attention, but policy alone will not fix the deeper issues. If we want clinical research to reflect the real world and deliver treatments that work for everyone, we have to rethink access from the ground up. That means meeting patients where they are, making the process less confusing, and treating diversity as part of doing the science right, not just another requirement to fulfill.
Blog written by Rima Vudutalapally
Sources:
[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC9133187/
[2] https://www.nejm.org/doi/full/10.1056/NEJMp2215609
[3] https://acrpnet.org/2025/10/07/diversity-and-inclusion-in-clinical-trials-practical-solutions-at-the-site-level